compound introduction
TSU-68 (SU6668; Orantinib)是多酪氨酸激酶受体抑制剂，对PDGFR自磷酸化抑制性最强，Ki为8 nM，还能相对弱地抑制VEGF-R1和FGF-R1。An antiproliferating agent and ATP-competitive PDGFR, Flk-1/KDR (VEGF), and FGFR inhibitor TSU-68 (SU6668, Orantinib) has greatest potency against PDGFR autophosphorylation with Ki of 8 nM in a cell-free assay, but also strongly inhibits Flk-1 and FGFR1 trans-phosphorylation, little activity against IGF-1R, Met, Src, Lck, Zap70, Abl and CDK2; does not inhibit EGFR. Phase 3. An antiproliferating agent and ATP-competitive PDGFR, Flk-1/KDR (VEGF), and FGFR inhibitor
